KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC

被引：6
|
作者：
Rudin, C. [1 ]
Shen, L. [2 ]
Pietanza, M. C. [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
KEYNOTE-604; pembrolizumab; small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.11.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-007
引用
收藏
页码：S2400 / S2400
页数：1
相关论文
共 50 条
  • [21] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Tabernero, J.
    Bang, Y.
    Van Cutsem, E.
    Fuchs, C.
    Janjigian, Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Qin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
  • [22] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [23] Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
    Yoon, Charles H.
    Ross, Merrick I.
    Gastman, Brian R.
    Luke, Jason J.
    Ascierto, Paolo A.
    Long, Georgina V.
    Rutkowski, Piotr
    Khattak, Muhammad
    Del Vecchio, Michele
    de la Cruz Merino, Luis
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Schadendorf, Dirk
    Carlino, Matteo S.
    Zhao, Yujie
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Gershenwald, Jeffrey E.
    Sondak, Vernon K.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2756 - 2764
  • [24] Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    Long, Georgina, V
    Dummer, Reinhard
    Humid, Omid
    Gajewski, Thomas F.
    Caglevic, Christian
    Dalle, Stephan
    Arance, Ana
    Carlino, Matteo S.
    Grob, Jean-Jacques
    Kim, Tae Min
    Demidov, Lev
    Robert, Caroline
    Larkin, James
    Anderson, James R.
    Maleski, Janet
    Jones, Mark
    Diede, Scott J.
    Mitchell, Tara C.
    LANCET ONCOLOGY, 2019, 20 (08): : 1083 - 1097
  • [25] Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer (vol 34, pg 3740, 2016)
    Reck
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) : 3327 - 3327
  • [26] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
    Rha, Sun Young
    Oh, Do-Youn
    Yanez, Patricio
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve A.
    Cil, Timucin
    Cruz, Felipe Melo
    Qin, Shukui
    Luo, Suxia
    Pan, Hongming
    Wainberg, Zev A.
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Wyrwicz, Lucjan S.
    LANCET ONCOLOGY, 2023, 24 (11): : 1181 - 1195
  • [27] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [28] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [29] Benmelstobart With Anlotinib Plus Chemotherapy as First-Line Therapy for ES-SCLC: A Randomized, Double-Blind, Phase 3 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 6 - 7
  • [30] ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
    Colombo, Nicoletta
    Coleman, Robert L.
    Wu, Xiaohua
    Kose, Fatih
    Wenham, Robert Michael
    Sebastianelli, Alexandra
    Hasegawa, Kosei
    Zsiros, Emese
    Rouge, Thibault De la Motte
    Bidzinski, Mariusz
    McNeish, Iain A.
    Sehouli, Jalid
    Korach, Jacob
    Debruyne, Philip R.
    Kim, Jae-Weon
    De Melo, Andrea C.
    Peng, Xuan
    Bogusz, Agata M.
    Yamada, Karin Sayuri
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345